Salesforce rises after TD Cowen lifts target to $300
Salesforce shares are trending after TD Cowen reiterated a Buy rating and raised its price target to $300 from $280, following strong quarterly results and expanding enterprise AI adoption.
Shares of Salesforce Inc. are moving higher Tuesday after TD Cowen analyst Derrick Wood reiterated a Buy rating and raised his price target to $300 from $280. The stock has climbed 40% from August lows after Salesforce’s late-August second-quarter results, a guidance increase and faster enterprise adoption of its proprietary AI platform. Salesforce reported total revenue of $11.35 billion, up 11% year over year and above analyst expectations, with current remaining performance obligations rising 14% in constant currency to $29.4 billion.
Management lifted its full-year fiscal revenue outlook by $200 million, or $300 million in constant currency, to $41.1 billion to $41.3 billion, and raised its full-year non-GAAP operating margin target to 34%. The update also followed reinforcement of its enterprise AI strategy. Salesforce expanded its strategic partnership with Anthropic alongside earnings to launch “Claudeforce.” The integration brings Claude’s reasoning models into Salesforce workflows, Agentforce and Slack, and includes a dedicated plugin with 37 pre-built sales skills for pipeline analysis, meeting prep and deal management.
Salesforce said it expects to spend about $300 million on Anthropic tokens in 2026 to support internal development across its 15,000 engineers. Chief Executive Marc Benioff described the second quarter as one of the best in company history, and said with Anthropic CEO Dario Amodei that combining Claude’s reasoning with Salesforce’s enterprise data lets AI agents carry out governed business actions rather than just answer questions. CRM shares were down 0.03% at $257.47 at the time of publication on Tuesday. The stock was near 52-week highs of $269.11 and was trading 22.1% above the 20-day SMA at $210.48 and 28.2% above the 200-day SMA at $200.45.
The 20-day SMA is above the 50-day SMA, but the longer-term crossover picture remains mixed with the 50-day SMA below the 200-day SMA. RSI is the clearest momentum gauge at 81.89, putting the stock firmly in overbought territory and suggesting the move may be stretched and more vulnerable to pullbacks or sideways digestion. Key resistance is $267.50, a nearby ceiling just below the 52-week high area where momentum runs can stall. Key support is $252.00, a recent pivot zone that could matter if the stock cools off from overbought levels.
Read also: Credo stock trades 22% above its 200-day average ahead of today's earnings.